Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-752-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees147
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable
Personalis (NASDAQ:PSNL) Frequently Asked Questions
What is Personalis' stock symbol?
Personalis trades on the NASDAQ under the ticker symbol "PSNL."
How were Personalis' earnings last quarter?
Personalis (NASDAQ:PSNL) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.22) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.03. The business had revenue of $17.20 million for the quarter, compared to analyst estimates of $15.77 million. The company's quarterly revenue was up 47.0% compared to the same quarter last year. View Personalis' Earnings History.
When is Personalis' next earnings date?
What price target have analysts set for PSNL?
5 analysts have issued twelve-month target prices for Personalis' stock. Their forecasts range from $22.00 to $29.00. On average, they anticipate Personalis' share price to reach $26.25 in the next year. This suggests a possible upside of 185.9% from the stock's current price. View Analyst Price Targets for Personalis.
What is the consensus analysts' recommendation for Personalis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.
Has Personalis been receiving favorable news coverage?
News articles about PSNL stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Personalis earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Personalis.
Are investors shorting Personalis?
Personalis saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 1,470,000 shares, an increase of 11.4% from the January 30th total of 1,320,000 shares. Based on an average daily volume of 440,500 shares, the short-interest ratio is presently 3.3 days. Currently, 9.0% of the company's stock are short sold. View Personalis' Current Options Chain.
Who are some of Personalis' key competitors?
Some companies that are related to Personalis include CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI) and Cancer Genetics (CGIX).
What other stocks do shareholders of Personalis own?
Who are Personalis' key executives?
Personalis' management team includes the folowing people:
- Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
- Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
- Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
When did Personalis IPO?
(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.
Who are Personalis' major shareholders?
Personalis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.08%), Nikko Asset Management Americas Inc. (3.08%), ARK Investment Management LLC (2.00%), Wellington Shields & Co. LLC (1.49%), Alyeska Investment Group L.P. (1.30%) and Wellington Shields Capital Management LLC (0.89%). View Institutional Ownership Trends for Personalis.
Which institutional investors are selling Personalis stock?
PSNL stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Bank of New York Mellon Corp, Kornitzer Capital Management Inc. KS and New York State Common Retirement Fund. View Insider Buying and Selling for Personalis.
Which institutional investors are buying Personalis stock?
PSNL stock was acquired by a variety of institutional investors in the last quarter, including Wellington Shields & Co. LLC, Alyeska Investment Group L.P., ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Candriam Luxembourg S.C.A., Wellington Shields Capital Management LLC and Gabelli Funds LLC. View Insider Buying and Selling for Personalis.
How do I buy shares of Personalis?
Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Personalis' stock price today?
One share of PSNL stock can currently be purchased for approximately $9.18.
How big of a company is Personalis?
What is Personalis' official website?
How can I contact Personalis?
Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]
MarketBeat Community Rating for Personalis (NASDAQ PSNL)
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
